Followers | 609 |
Posts | 26743 |
Boards Moderated | 1 |
Alias Born | 08/12/2010 |
Monday, April 09, 2018 10:52:59 PM
Yes there are trials and information....
CONFERENCE IN MAY 2018 TO SHOW THE WORLD!!!
I through together quickly. Headed out with wife to dinner.
Creative Medical Technology Holdings Announces Superior Immune Modulatory of AmnioStem Stem Cells Compared to other Stem Cell Types
April 4, 2018
https://www.marketwatch.com/story/creative-medical-technology-holdings-announces-superior-immune-modulatory-of-amniostem-stem-cells-compared-to-other-stem-cell-types-2018-04-04
Creative Medical Technology Holdings, Inc. To Unveil Its Patented CaverStem™ Procedure For Erectile Dysfunction At International Urology ConferencePress Release | 03/26/2018
Creative Medical Technology Holdings, Inc. To Unveil Its Patented CaverStem™ Procedure For Erectile Dysfunction At International Urology Conference
March 26, 2018
https://www.otcmarkets.com/stock/CELZ/news/Urologist-to-the-Stars-Dr-Alexander-Gershman-Begins-Treating-Patients-with-Patented-Caverstem-Stem-Cell-Procedure-for-Dr?id=178362
Creative Medical Technology Holdings Announces Commercialization of patented Stem Cell Procedure for Erectile Dysfunction
Trial Results Support Initiation of Urologist Outreach and Commercialization
https://www.otcmarkets.com/stock/CELZ/news/Creative-Medical-Technology-Holdings-Recruits-Top-Urologists-for-Caverstem-Stem-Cell-Treatment-of-Erectile-Dysfunction?id=178171
Creative Medical Technology Holdings Recruits Top Urologists for Caverstem™ Stem Cell Treatment of Erectile DysfunctionPress Release | 12/14/2017
Creative Medical Technology Holdings Recruits Top Urologists for Caverstem™ Stem Cell Treatment of Erectile Dysfunction
December 14, 2018
With other clinical trials validating the safety and efficacy of this procedure to treat erectile dysfunction in patients who do not respond to currently available treatments, management has reported increased interest in the technology by urologists. Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.
"The CaverstemTM procedure, uses the patient's own bone marrow derived stem cells to stimulate arterial, venous and smooth muscle regeneration, and is an outpatient procedure performed by urologists in their medical facilities. We are using a patient's own cells and we do not manipulate the stem cells through the use of chemicals, growth factors or expansion and have experienced no procedure-related safety issues," said Dr. Thomas Ichim Co-Founder and Chief Scientific Officer of Creative Medical Technology Holdings, Inc.
The ongoing clinical trial covering patients ages 18 to 80 received Institutional Review Board (IRB) approval in December 2016. The trial was sponsored by Creative Medical Technology Holdings, Inc. based on our patented technology and was conducted at the Los Angeles Biomedical Institute at Harbor – UCLA Hospital in Torrance, CA.
"We are pleased to have received such enthusiasm from the Urology community in the first 30 days of commercialization and we anticipate similar responses as we expand our physician base throughout the United States," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings, Inc.
https://www.otcmarkets.com/stock/CELZ/news/Creative-Medical-Technology-Holdings-Recruits-Top-Urologists-for-Caverstem-Stem-Cell-Treatment-of-Erectile-Dysfunction?id=178171
Creative Medical Technology Holdings Announces Commercialization of patented Stem Cell Procedure for Erectile Dysfunction
Trial Results Support Initiation of Urologist Outreach and Commercialization
October 19, 2017
https://www.otcmarkets.com/stock/CELZ/news/Creative-Medical-Technology-Holdings-Announces-Commercialization-of-patented-Stem-Cell-Procedure-for-Erectile-Dysfunctio?id=172855
ED patient Information:
http://www.creativemedicaltechnology.com/erectile-dysfunction/science/information-for-patients/
First Human proof of Concept
http://www.creativemedicaltechnology.com/erectile-dysfunction/science/
ALL POSTS are just my opinion! Never BUY/SELL stock based on only them! Perform your own DD and make your own decision!
Recent CELZ News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/17/2024 08:01:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/29/2023 09:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 01:00:18 PM
- Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements • PR Newswire (US) • 06/28/2023 12:00:00 PM
- Creative Medical Technology Announces $2 Million Share Repurchase Program • PR Newswire (US) • 06/12/2023 12:01:00 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 06/12/2023 12:00:00 PM
- Creative Medical Technology Holdings Announces Reverse Stock Split • PR Newswire (US) • 06/09/2023 04:30:00 PM
- Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform • PR Newswire (US) • 05/31/2023 12:00:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM